Targeting telomerase

Aisha Siddiqa, David A. Cavazos, Robert A Marciniak

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10% to 15% of immortalized cancer cells that do not express telomerase use a recombination-based mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance.

Original languageEnglish (US)
Pages (from-to)378-390
Number of pages13
JournalRejuvenation Research
Volume9
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Telomerase
Telomere
Telomere Homeostasis
Neoplasms
Therapeutics
Genetic Recombination
Immunization
Vaccines
Maintenance
DNA

ASJC Scopus subject areas

  • Aging

Cite this

Targeting telomerase. / Siddiqa, Aisha; Cavazos, David A.; Marciniak, Robert A.

In: Rejuvenation Research, Vol. 9, No. 3, 09.2006, p. 378-390.

Research output: Contribution to journalArticle

Siddiqa, A, Cavazos, DA & Marciniak, RA 2006, 'Targeting telomerase', Rejuvenation Research, vol. 9, no. 3, pp. 378-390. https://doi.org/10.1089/rej.2006.9.378
Siddiqa, Aisha ; Cavazos, David A. ; Marciniak, Robert A. / Targeting telomerase. In: Rejuvenation Research. 2006 ; Vol. 9, No. 3. pp. 378-390.
@article{35cbc524d3814d46a03422fa7e94624b,
title = "Targeting telomerase",
abstract = "Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10{\%} to 15{\%} of immortalized cancer cells that do not express telomerase use a recombination-based mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance.",
author = "Aisha Siddiqa and Cavazos, {David A.} and Marciniak, {Robert A}",
year = "2006",
month = "9",
doi = "10.1089/rej.2006.9.378",
language = "English (US)",
volume = "9",
pages = "378--390",
journal = "Rejuvenation Research",
issn = "1549-1684",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Targeting telomerase

AU - Siddiqa, Aisha

AU - Cavazos, David A.

AU - Marciniak, Robert A

PY - 2006/9

Y1 - 2006/9

N2 - Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10% to 15% of immortalized cancer cells that do not express telomerase use a recombination-based mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance.

AB - Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10% to 15% of immortalized cancer cells that do not express telomerase use a recombination-based mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance.

UR - http://www.scopus.com/inward/record.url?scp=33746689124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746689124&partnerID=8YFLogxK

U2 - 10.1089/rej.2006.9.378

DO - 10.1089/rej.2006.9.378

M3 - Article

C2 - 16859479

AN - SCOPUS:33746689124

VL - 9

SP - 378

EP - 390

JO - Rejuvenation Research

JF - Rejuvenation Research

SN - 1549-1684

IS - 3

ER -